The clinical utility of faecal calprotectin in patients with differentiated and undifferentiated spondyloarthritis: Relevance and clinical implications

Emad, Yasser; Ragab, Yasser; Hammam, Nevin; El-Shaarawy, Nashwa; Fawzi, Magdy; Amer, Arwa S.; Elmakhzangy, Hesham; Ismail, Ahmed; Ibrahim, Omer H. M.; Hassan, Yosra M.; Kamal, Ahmed; Rasker, Johannes J.

doi:10.1016/j.reuma.2020.10.002

Cited by 5 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we showed that faecal CP levels in psoriatic patients were higher than the normal range and these levels decreased after 24 weeks of biological therapy, in particular anti-IL23. These results were partially in line with studies from the literature, in fact the increase in CP levels (serum and faecal) were investigated in various inflammatory diseases such as axial spondyloarthritis (axSpA), rheumatoid arthritis (RA), IBD, PsA and psoriasis [ 30 , 31 , 32 , 33 ].…”

Section: Discussionsupporting

confidence: 87%

Evaluation of the Role of Faecal Calprotectin in the Management of Psoriatic Patients under Treatment with Biologic Drugs

et al. 2022

View full text Add to dashboard Cite

Background: Fecal calprotectin has emerged as a significant, validated, and non-invasive biomarker allowing for the evaluation of inflammatory bowel disease. Our study assessed the reliability of the use of faecal calprotectin as a valuable tool in the management of psoriatic patients on biological therapy. Methods: This was a single-centre prospective study including adult patients affected by moderate-to-severe psoriasis starting biological therapy. Faecal calprotectin levels were evaluated at baseline and at week 24 (W24) of treatment in all enrolled patients. Results: Overall, 129 patients were enrolled. The mean baseline faecal calprotectin levels were 74.7 μg/g and a significant reduction was detected at W24 of biological therapy (57.5 μg/g). An analysis of faecal CP values stratified by therapy type was performed. No significant reduction was assessed at W24 for any of the anti-IL17 drugs, whereas a significant reduction was detected for all IL23 inhibitors. Conclusions: Our study showed the potential use of faecal CP levels as a valuable tool for exploring intestinal inflammation in the management of psoriatic patients undergoing treatment with biologic drugs.

show abstract

Section: Discussionsupporting

confidence: 87%

Evaluation of the Role of Faecal Calprotectin in the Management of Psoriatic Patients under Treatment with Biologic Drugs

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In some patients has been observed the involvement of the vascular, neurologic, and gastrointestinal (GI) systems. In their work, Özşeker et al [ 21 ] estimated the usefulness of FC in the detecting intestinal involvement in patients with BD. Their study included 30 subjects affected by BD and 25 healthy volunteers as a control group.…”

Section: Fecal Calprotectin and Rheumatologic Diseasesmentioning

confidence: 99%

“…No statistically significant differences were found in other inflammatory markers such as C reactive protein (CRP). Subjects with intestinal involvement as ileitis and ulcers in the terminal ileum showed a significantly increase level of FC compared to the group with negative intestinal involvement [ 21 ]. Another study confirms these results and suggest FC as a useful tool for diagnosis gastrointestinal involvement in patients with BD.…”

Section: Fecal Calprotectin and Rheumatologic Diseasesmentioning

confidence: 99%

Gastrointestinal Involvement in Extra-Digestive Disease: Which Is the Role of Fecal Calprotectin?

et al. 2022

View full text Add to dashboard Cite

Fecal calprotectin (FC) is a very sensitive marker of inflammation of the gastrointestinal tract. Its clinical utility can be appreciated in both intestinal and extraintestinal diseases. Recent evidence suggests a link between intestinal inflammation and dermatological, rheumatic and neurological diseases. This review focuses on the role of FC in non-gastrointestinal disease, such as rheumatic, dermatologic, neurologic and last but not least SARS-CoV-2 infection.

show abstract

Screening of silent inflammatory bowel disease in seronegative spondyloarthritis patients: Fecal calprotectin, ileo-colonoscopy and histopathology assessment

Badran,

Saweres,

GamalEldeen

et al. 2024

The Egyptian Rheumatologist

View full text Add to dashboard Cite

The clinical utility of faecal calprotectin in patients with differentiated and undifferentiated spondyloarthritis: Relevance and clinical implications

Cited by 5 publications

References 30 publications

Evaluation of the Role of Faecal Calprotectin in the Management of Psoriatic Patients under Treatment with Biologic Drugs

Evaluation of the Role of Faecal Calprotectin in the Management of Psoriatic Patients under Treatment with Biologic Drugs

Gastrointestinal Involvement in Extra-Digestive Disease: Which Is the Role of Fecal Calprotectin?

Screening of silent inflammatory bowel disease in seronegative spondyloarthritis patients: Fecal calprotectin, ileo-colonoscopy and histopathology assessment

Contact Info

Product

Resources

About